The UK National Health Service (NHS) announced on October 17 that Roche's glofitamab (also known as Columvi®), after receiving approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE), will be used for patients with previously treated diffuse large B-cell lymphoma (DLBCL).
NHS to Offer Roche's Columvi for Blood Cancer Patients Following Regulatory Approvals
Oct 17, 2023 17:59
CST Updated
17:59
Roche
Oncology Drug Research, Development, and Manufacturing
National Health Service
The NHS was launched in 1948. It stems from the long-held ideal that everyone should have access to good healthcare, regardless of wealth—one of the core principles of the NHS. Apart from certain charges (such as those for prescriptions, optical services, and dental care), the NHS in England remains free at the point of use for all UK residents. The UK’s population currently exceeds 64.6 million, with 54.3 million people living in England alone. The NHS treats more than one million patients every 36 hours. Its services cover a comprehensive range of care, including antenatal check-ups, routine examinations (such as the NHS Health Check), treatment for long-term conditions, transplants, emergency care, and end-of-life care.